Marc Comas, managing director of Accord Healthcare Iberia, highlights the footprint of the company as the leading generics and biosimilars player in the Spanish hospital sector and how his early strategy when founding the affiliate has set them up for long-term success. Furthermore, he points out the dynamics of the Spanish biosimilars ecosystem and his plans to double revenue over the next five years.
Unlike competitor generics companies now struggling to find profitability, we remained focused on hospitals and have a very lean operation, with revenues of over EUR 50 million
